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Abstract: Entry inhibitors represent a new class of antiretroviral agents for the treatment of 
infection with HIV-1. While resistance to other HIV drug classes has been well described, 
resistance to this new class is still ill defined despite considerable clinical use. Several 
potential mechanisms have been proposed: tropism switching (utilization of CXCR4 instead 
of CCR5 for entry), increased affinity for the coreceptor, increased rate of virus entry into 
host cells, and utilization of inhibitor-bound receptor for entry. In this review we will 
address the development of attachment, fusion, and coreceptor entry inhibitors and explore 
recent studies describing potential mechanisms of resistance. 
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1. Overview of HIV-1 Antiretroviral Therapy 
The major approach to the medical management of HIV infection is the treatment of patients with 
antiviral drugs. The enzymatic processes of the HIV-1 replication cycle present unique approaches for 
targeted disruption by pharmacological agents. Due to the high rates of virus production and the 
mutation rate of the virus [1], treatment of HIV-1 infection generally includes administration of three 
agents in combination, referred to as highly active antiretroviral therapy (HAART). Sustained 
treatment of patients with three active drugs results in suppression of viral replication in peripheral 
blood to below detection limits of sensitive clinical assays (<50 RNA copies/ml). Continued virologic 
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suppression has led to dramatic increases in the life expectancy of HIV-infected individuals and in 
time to diagnosis with AIDS, and decreases in HIV-associated morbidity and opportunistic infection 
[2]. To date, 24 individual drugs have been approved by the United States Food and Drug 
Administration for the treatment of HIV infection. These drugs are distributed into six major classes: 
1) Nucleoside-analog reverse transcriptase inhibitors (NRTI), 2) Non-nucleoside reverse transcriptase 
inhibitors (NNRTI), 3) Protease inhibitors (PI), 4) Fusion inhibitors, 5) Entry Inhibitors - Coreceptor 
Antagonists, and 6) Integrase inhibitors (Table 1).  
Table 1. FDA approved therapeutics for the treatment of HIV infection [3]. 
NRTI – nucleoside reverse transcriptase inhibitor; NNRTI – non-nucleoside reverse transcriptase 
inhibitor; PI – protease inhibitor. 
Brand Name  Generic Name  Class  Manufacturer  Approval Date 
Emtriva  emtricitabine, FTC  NRTI  Gilead Sciences  07/02/03 
Epivir Lamivudine,  3TC  NRTI  GlaxoSmithKline  11/17/95 
Hivid Zalcitabine,  ddC  NRTI Hoffmann-LaRoche  06/19/92 
Retrovir Zidovudine,  AZT  NRTI  GlaxoSmithKline  03/19/87 
Videx  Didanosine, ddI  NRTI  Bristol-Myers Squibb  10/09/91 
Viread Tenofovir,  TDF  NRTI  Gilead  Sciences  10/26/01 
Zerit  Stavudine, d4T  NRTI  Bristol-Myers Squibb  06/24/94 
Ziagen Abacavir,  ABC  NRTI  GlaxoSmithKline  12/17/98 
Intelence Etravirine,  ETV  NNRTI Tibotec  Therapeutics  01/18/08 
Rescriptor Delavirdine,  DLV  NNRTI  Pfizer  04/04/97 
Sustiva  Efavirenz, EVF  NNRTI  Bristol-Myers Squibb 09/17/98 
Viramune Nevirapine,  NVP  NNRTI Boehringer  Ingelheim 06/21/96 
Agenerase Amprenavir,  APV  PI  GlaxoSmithKline 04/15/99 
Aptivus  Tipranavir, TPV  PI  Boehringer Ingelheim 06/22/05 
Crixivan Indinavir,  IDV PI  Merck  03/13/96 
Invirase Saquinavir,  SQV PI  Hoffmann-LaRoche 12/06/95 
Lexiva Fosamprenavir,  APV PI  GlaxoSmithKline 10/20/03 
Norvir  Ritonavir, RTV  PI  Abbott Laboratories  03/01/96 
Prezista Darunavir  PI  Tibotec, Inc.  06/23/06 
Reyataz  Atazanavir, ATV  PI  Bristol-Myers Squibb 06/20/03 
Viracept Nelfinavir,  NFV  PI  Agouron  03/14/97 
Fuzeon Enfuvirtide,  T-20  Fusion  Hoffman-LaRoche 
and Trimeris 
03/13/03 
Selzentry Maraviroc,  MVC  CCR5/entry  Pfizer  08/06/07 
Isentress Raltegravir,  RTV  Integrase  Merck  10/12/07 Viruses 2010, 2                                       
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2. HIV-1 Envelope and Host Cell Entry 
HIV-1 can productively infect cells that express two receptors: the principal receptor CD4 [4] and 
an auxiliary co-receptor, which derives from the chemokine receptor family, typically either CCR5 or 
CXCR4 [5] (Figure 1). HIV-1 enters cells through a pH-independent membrane fusion event [6], 
which results in release of the core particle into the cytoplasm. However, recent studies now describe 
HIV-1 entry and membrane fusion following endocytosis [7,8]. The principal virus protein involved in 
entry is the envelope glycoprotein. The envelope gene encodes a protein that measures 160 kDa when 
fully glycosylated and is divided into two regions: the surface unit gp120 and the transmembrane 
region gp41 [9]. The gene is translated as a full length gp160 precursor protein and undergoes 
secondary structure formation and glycosylation in the endoplasmic reticulum [10]. Gp160 monomers 
then oligomerize into trimers [11] via noncovalent interactions between gp41 subunits. Processing of 
the protein in the golgi apparatus results in cleavage of the 160 kDa protein by members of the furin 
family of endoproteases into the gp120 and gp41 subunits [12]. The gp120 surface unit remains 
noncovalently associated with its gp41 partner [13]. The envelope is transported to the cell surface and 
is incorporated into virions budding from the plasma membrane.  
When interacting with a new target cell, gp120 initially makes contact with the N-terminus of CD4 
[14] through interactions with a conserved binding site [15] (Figure 1B). Interaction with CD4 results 
in considerable reconfiguration of the gp120 molecule which results in exposure of a highly conserved 
coreceptor binding site [16-20] (Figure 1C). The coreceptor binding site interacts with the N-terminus 
of a coreceptor, either CCR5 or CXCR4 (Figure 1C). Further coreceptor interactions are mediated by 
amino acids at the crown of the V3 loop. Ultimately, conformational changes in the envelope 
glycoprotein expose the fusion peptide, a sequence of 15 hydrophobic amino acids located on the N-
terminus of gp41, which insert into and destabilize the host cell membrane [21,22]. At this stage, gp41 
is an integral component common to the viral envelope and host membrane (Figure 1D). However, 
further structural transitions in gp41 are necessary to provide the significant change in free energy 
required to drive membrane fusion [23-25]. Prior to fusion, gp41 folds back on itself forming a hairpin 
structure, the function of which is to bring into close proximity the fusion peptide associated cellular 
membrane and the integral gp41 associated viral membrane (Figure 1E). This process is mediated by 
two helical regions in the ectodomain of gp41 termed HR1 and HR2 [26-28]. The N-terminal heptad 
repeat region, or HR1, and the C-terminal heptad repeat region, or HR2, form a stable 6-helix bundle 
when the antiparallel HR2 domain binds on the outer grooves of the triple-stranded coiled-coil HR1 
domain, resulting in the localization of the fusion peptide and transmembrane domains at the same end 
of the molecule [29,30] (Figure 1F). This re-orientation and release of free energy drives the fusion of 
the viral and host cell membranes. Viruses 2010, 2                                       
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Figure 1. HIV-1 Entry. (a)  Virus entry into host cells is mediated by the envelope 
glycoprotein. The major events of the entry process are divided into receptor binding and 
membrane fusion events. The functional unit of envelope is a trimer composed of three 
gp41 molecules (blue bars) and three gp120 molecules (blue spheres), which are associated 
by non-covalent interactions. (b) Virus entry is initiated by the attachment event, binding 
of gp120 to host cell CD4 (green spheres). Binding to CD4 results in reconfiguration of the 
gp120 molecule. The bridging sheet is formed and gp120 is primed for interaction with a 
coreceptor molecule. (c) CD4-bound gp120 interacts with a coreceptor, either CCR5 or 
CXCR4. The stoichiometry of the ternary complex is 1:1:1 (gp120:CD4:Coreceptor), 
though the number of trimer subunits and number of trimers required to initiate membrane 
fusion is unclear. (d) After interaction with the coreceptor, a hydrophobic gp41-derived 
peptide (the fusion peptide) is inserted into the host cell membrane. (HIV-1 gp120, CD4 
molecules, and coreceptor molecules have been removed for simplification, and to allow 
focus on the transition in gp41 during fusion) This event anchors the virus to the host cell, 
and the gp41 molecule acts as a bridge between the viral and cellular membranes. 
Structural rearrangements within the gp41 molecule are mediated by two triple stranded 
coiled-coils, the C-terminal (red) and N-terminal (blue) heptad repeat domains. (e) 
Metastable prefusion intermediates occur during the reconfiguration of the gp41 domains. 
(f) The C- and N-terminal heptad repeat regions pack into one another forming a stable six-
helix bundle. This results in a close approximation of viral and host cell membrane and the 
formation of a fusion pore. The initial fusion pore enlarges as the membrane lipids mix, 
ultimately leading to a fusion pore of critical size for release of the viral core into the 
cytoplasm.  
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3. HIV-1 Receptors and Implications of Tropism 
The concept of inhibiting HIV-1 replication by preventing the virus from entering the host cell has 
been contemplated since the first identification of the major receptor, CD4 [4,14]. Early approaches 
suggested the use of monoclonal antibodies to CD4 to block binding by virus. This approach was 
limited due to the importance of CD4 in basic immunologic functions. The next major advancement in 
inhibition of HIV-1 entry was the development of a soluble form of CD4 (sCD4) [31-35], which could 
inhibit HIV-1 replication in vitro and in vivo [36,37], as well as a soluble CD4-immunoglobulin fusion 
protein [38]. However, laboratory strains were significantly more sensitive to sCD4 neutralization than 
primary HIV-1 isolates. These differences were based on affinity and association rates for CD4 of the 
envelope glycoprotein quaternary structure [39,40]. In some cases, treatment with sCD4 resulted in 
enhancement of infection [2]. Ultimately it was observed that therapeutic administration of sCD4 had 
no effect on viremia or disease [41,42]; however, the sCD4 molecule provided a tool for greater 
understanding of the process of HIV-1 entry.  
Discovery of the coreceptors that mediate HIV-1 entry was facilitated by studies showing that 
replication of virus could be blocked by then unknown, leukocyte derived, soluble suppressor factors 
[43]. The soluble factors derived from CD8
+ T cells were identified as the C-C chemokines RANTES 
(CCL5), MIP-1α (CCL3), and MIP-1β (CCL4) [44]. Chemokines are small paracrine signaling 
molecules that are principally involved in the inflammatory response. There are currently four main 
classes of chemokines, and their nomenclature is based on the number and orientation of N-terminal 
cysteine motifs [45]. C chemokines have a single cysteine residue. C-C chemokines, C-X-C 
chemokines, and C-X3-C chemokines each have two cysteine residues, separated by 0, 1, or 3 other 
residues, respectively. Only the C-C chemokines and C-X-C chemokines are major factors in HIV-1 
infection.  
In 1996 the “fusin” cofactor was identified by expression of a cDNA library derived from T-tropic 
virus-permissive cells against a nonpermissive cell line [46]. This receptor was later identified as C-X-
C chemokine receptor 4 (CXCR4), and its ligands [stromal derived factor-1 α/β (SDF-1α/β, CXCL12)] 
can inhibit HIV-1 replication in vitro [47,48]. Shortly thereafter, C-C chemokine receptor 5 (CCR5) 
was identified as the major entry cofactor of M-tropic, NSI HIV-1 isolates [49-53]. The chemokine 
receptors are members of the seven transmembrane G protein-coupled receptor superfamily. They are 
defined by their coupling to the pertussis toxin-sensitive Gi class of G proteins, expression in 
leukocytes, and chemotactic signaling function, and are primarily involved in leukocyte activation and 
directional migration. The chemokine system is highly redundant, with each receptor capable of 
binding multiple ligands, and each ligand promiscuously binding to multiple receptors. This same 
promiscuity has been investigated for the HIV-1 envelope, and it was revealed that the chemokine 
receptors CCR2b, CCR3, CCR7, CCR8, STRL33/BONZO, and gpr15/BOB can mediate infection of 
cells by some viruses [54-58]. Use of these alternative coreceptors appears limited to expression on 
transfected cell lines, and most evidence suggest that the receptors CCR5 and CXCR4 are the most 
relevant receptors in vivo. Currently, viruses that utilize CCR5 as an entry cofactor are referred to as 
R5 viruses, while viruses that utilize CXCR4 are referred to as X4 viruses [59]. Viruses that can utilize 
either CCR5 or CXCR4 as an entry cofactor are referred to as dual tropic, or R5X4.  Viruses 2010, 2                                       
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CCR5-tropism is characteristic of viral isolates that persist during asymptomatic disease, and are 
further thought to be the principal subset of virus responsible for new infections. Over the course of 
HIV infection, a switch to primarily CXCR4-tropic or dual tropic isolates is generally associated with 
a rapid depletion of CD4
+ T cells and progression to AIDS [60-62]. A subset of individuals at high risk 
for infection with HIV-1 remains seronegative despite multiple opportunities for virus transmission. 
Genetic analysis of these cohorts revealed that a subset of these individuals was homozygous for a  
32 bp deletion in the CCR5 open reading frame, and that their CD4
+ T cells were resistant to infection 
by R5 viruses ex vivo [63-68]. This deletion (Δ32) results in a truncated receptor that is not expressed 
on the cell surface. The 32 allele is present in the Caucasian population, with as many as 20% of 
Caucasians heterozygous for the mutation (32/wt) and 1% homozygous (32/32) [63]. While 
individuals homozygous for the Δ32 allele are highly resistant to acquisition of HIV-1 infection 
(transmission of X4 viruses in Δ32/Δ32 individuals has been reported), heterozygous individuals 
typically have a more protracted course of infection and experience longer time intervals before 
progression to AIDS. Single nucleotide polymorphisms within the promotor region of CCR5 have also 
been associated with differences in disease progression rates. Specifically, individuals who are –
2459A/A have been shown to progress to AIDS more rapidly than individuals homozygous for the 
guanine allele (-2459G/G) [69-72]. Remarkably, individuals carrying these receptor polymorphisms 
lack any discernable biological phenotype other than resistance to HIV infection or delayed 
progression to AIDS, which indicated the potential value of targeting entry through the CCR5 
coreceptor as a viable pharmacological intervention. The origin of the ∆32 deletion in human or 
primate evolution is unknown but the impact of this polymorphism is differential depending on 
pathogen. The ∆32 mutation has been shown to be protective against viral persistence with hepatitis B 
virus infection [73]. In contrast, heterozygotes and homozygotes for the ∆32 CCR5 deletion are at 
higher risk of early and rapid disease progression upon West Nile virus infection [74]. 
4. Interaction of HIV-1 Envelope and CCR5 
The envelope glycoprotein, when unligated with CD4, is not in a conformation that can interact 
with the coreceptor. A subset of HIV-2 viruses and SIV isolates can bind to coreceptor independently 
of CD4, which has led to the suggestion that the chemokine receptors are the ancestral receptors of the 
early lineage viruses that gave rise to modern primate immunodeficiency viruses. Use of CD4 is 
thought to be an adaptation to hide the conserved coreceptor binding site from recognition by the host 
humoral response. When gp120 binds CD4, structural rearrangements in the envelope glycoprotein 
lead to exposure of the V3 loop and the formation of the bridging sheet. The V3 loop is a highly 
heterogeneous, loop-like structure within gp120. The V3 loop is the immunodominant domain of the 
HIV-1 envelope, though it is not exposed on most primary isolates and is therefore not considered a 
major neutralization determinant [75]. The V3 loop is topographically divided into three subsections 
(Figure 2): 1) The base, formed by a disulfide bond and in close approximation with the gp120 core; 2) 
the stem, which is a flexible linker region between the base and the tip; 3) the crown, which contains a 
helix-turn-helix motif defined by a G-P-G-X sequence, and believed to be a critical interacting face 
with the extracellular loops of CCR5. V3 is the critical determinant of coreceptor tropism. As few as 
two amino acid changes in the V3 loop can alter the coreceptor specificity from CCR5 to CXCR4 [75]. Viruses 2010, 2                                       
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Furthermore, changes in the V3 have been specifically associated with changes in susceptibility to 
entry inhibitors [75]. In addition to the V3 loop, the V1/V2 regions of gp120 have been shown to direct 
co-receptor activity and influence co-receptor affinity [76]. 
The current model of gp120-CD4-CCR5 ternary complex formation favors multiple interactions 
between gp120 and CCR5 (Figure 2). Studies using deletions and chimeric receptors (using parts of 
human CCR2b or murine CCR5, which do not mediate HIV-1 entry) suggest that the N-terminus of 
CCR5 is significant for HIV-1 entry [16,77,78]. Site directed mutagenesis of the V3 region indicated 
that two domains in gp120 were essential to the interaction with CCR5. The V3 tip, or crown, is 
suggested to interact with the extracellular loops of CCR5, specifically extracellular loop 2 [79]. 
Consistent with this, monoclonal antibodies that recognize CCR5 ECL2 potently inhibit HIV-1 entry. 
Post-translational modification of CCR5 plays a significant role in coreceptor activity. The N-terminus 
undergoes both O-glycosylation and tyrosine sulfation. Inhibition of tyrosine sulfation pathways 
decreases CCR5 binding by gp120 and HIV-1 entry [80]. Mutagenesis or deletion of the intracellular 
carboxy-terminal domain of CCR5, which mediates ligand-induced endocytosis, reveals that this is not 
an essential function of viral entry. Similarly, deletion or mutagenesis of the second intracellular loop 
DRY signaling motif indicates that intracellular signaling is dispensable for productive viral entry.  
Figure 2. Model of Ternary Complex Formation. The model is based on the crystal 
structure of a V3 loop-containing structure of gp120, bound to a soluble fragment of CD4 
[81]. The gp120 core (blue) is bound to the first Ig-like domain of CD4 (cyan). This 
interaction stabilizes the core molecule bridging sheet domain, which is composed of a 
series of antiparallel β-sheets. The V3 loop (yellow) extends outward from the gp120 core 
inner domain. The V3 crown is thought to mediate interaction with the second extracellular 
loop of CCR5 (black). The CCR5 N-terminus is thought to contact both the bridging sheet 
domain as well as the V3 base.  
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Seven transmembrane G protein-coupled receptors exist in multiple allosteric states due to their 
function in transmitting information from a single ligand binding site to other, topographically distinct 
locales, which include sites of G protein association, oligomerization, and signal transduction 
scaffolding protein binding [82]. As such, CCR5 exists in multiple antigenic configurations [83]. 
Distinct conformational states of CCR5 in either active or inactive states have been observed using the 
binding properties of various antibodies [83,84]. These conformational states exist transiently, and the 
stability of each conformation depends upon the lipid environment, the activation state of the receptor, 
and the ligand that is bound. Environmental stimuli can stabilize the receptor in particular antigenic 
configurations. Stabilization may potentially occur through receptor association with scaffolding 
proteins involved in signal transduction. Some reports suggest that CCR5 dimerizes through 
interactions in the first transmembrane region, and that the dimerized form of the molecule is non-
permissive for HIV-1 entry [85]. Dimerization of CCR5 has been suggested to be ligand-dependent, 
though some studies have demonstrated ligand-independent oligomerization of CCR5 [86]. The role of 
CCR5 conformational heterogeneity in HIV-1 entry and coreceptor interaction remains unclear at this 
time. It remains unknown whether HIV-1 envelope can interact with all, or only a subset of the 
available CCR5 conformational isomers. 
5. Inhibition of HIV-1 Entry 
The major enzymatic processes of HIV-1 replication are reverse transcription, integration, and 
protease maturation. Each represents a unique, virus specific event that can be targeted by drugs to 
block virus replication. Uncovering the major mechanisms of HIV-1 host cell entry revealed a series of 
critical processes that could be targeted for disruption pharmacologically. HIV-1 entry inhibitors fall 
into three major classes based on the specific entry process that they target: 1) attachment inhibitors, 
which block the interaction between HIV-1 envelope and CD4, 2) coreceptor inhibitors, which block 
the interaction between HIV-1 envelope and CCR5 or CXCR4, and 3) fusion inhibitors, which prevent 
the virus from mixing its membrane with the host cell membrane and releasing the viral core into the 
cytoplasm (Table 2).  
5.1. Attachment Inhibitors 
The attachment inhibitor BMS-378806 inhibits both R5- and X4-tropic HIV-1 isolates [87]. This 
compound binds to a pocket on gp120 important for binding CD4 and alters the conformation of the 
protein such that it cannot recognize CD4 [88]. The inhibitor binds with significantly higher affinity 
than CD4, and is an excellent candidate for therapeutic use. TNX-355 is a humanized anti-CD4 
monoclonal antibody that binds to CD4 and inhibits HIV-1 envelope docking, but does not inhibit CD4 
function in immunological contexts. Currently no attachment inhibitors are approved for use in 
patients with HIV-1 infection and none appear to be approaching phase I clinical trials. 
5.2. Fusion Inhibitors and Mechanisms of Resistance 
The crystal structure of the gp41 ectodomain [29] and of the ectodomain partnered with an 
inhibitory peptide (C34) [89] revealed that the fusion active conformation of gp41 was a six-helix Viruses 2010, 2                                       
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bundle in which three N-helices form an interior, trimeric coiled-coil onto which three antiparallel C-
helices pack. Enveloped viruses use a generally conserved mechanism to initiate the fusion event 
between viral and host cell membranes, and this six-helix bundle formation has been well studied in 
the paramyxoviruses family of viruses [10,90]. Peptide fusion inhibitors were designed based on the 
discovery that two homologous domains in the viral gp41 protein must interact with each other to 
promote fusion, and that mimicry of one of these domains by a heterologous protein can bind and 
disrupt the intramolecular interactions of the virus protein. Alpha-helical peptides homologous to the 
leucine zipper domain of gp41 had significant antiviral activity against HIV-1, and this activity 
depended upon their ordered solution structure [91]. Rational design ultimately produced a molecule 
(T-20, enfuvirtide) with potent antiviral activity in vivo [92,93], and many other peptide mimics have 
been described (Table 2).  
Table 2. Investigational Entry Inhibitors. 
Compound Mechanism  Status  Manufacturer 
T-20 Fusion  inhibitor  Approved  Trimeris 
T-1249 Fusion  inhibitor  Discontinued  Trimeris 
C-34  Fusion inhibitor  Preclinical only  --- 
5-Helix Fusion  inhibitor  ---  --- 
Maraviroc CCR5  antagonist  Approved  Pfizer 
Vicriviroc (SCH-D)  CCR5 antagonist  Phase III  Schering-Plough 
SCH-C  CCR5 antagonist  Phase I  Schering-Plough 
AD101  CCR5 antagonist  Preclinical only  Schering-Plough 
Aplaviroc CCR5  antagonist  Discontinued  from 
Phase I 
GlaxoSmithKline 
TAK-652  CCR5 antagonist  Phase I  Takeda 
TAK-779  CCR5 antagonist  Preclinical only  Takeda 
INCB 9471  CCR5 antagonist  Phase IIa  Incyte 
AMD3100  CXCR4 antagonist  Phase I/II  AnorMED 
PRO-140 Humanized  anti-CCR5 monoconal 
antibody 
Phase IIa  Progenics 
PSC-RANTES Chemokine  analog  (Microbicide)  Gryphon 
BMS-378806 Attachment  inhibitor  Phase IIa  Bristol-Myers Squibb 
PRO-542 CD4-Ig  fusion  Discontinued  Progenics 
TNX-355  Anti-CD4 monoclonal antibody  Phase IIa  Biogen Idec; Tanox 
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Resistance to early alpha-helical inhibitors was mediated by mutations in the N-terminal heptad 
repeat region of gp41 [94], providing evidence of the specificity of binding of these peptides to the 
virus. Monotherapy with enfuvirtide resulted in viral load rebounds after 14 days of therapy, and 
resistance determinants mapped to the HR1 domain (G36D, I37T, V38A, V38M, N42T, N42D, N43K) 
[95]. Mutations that confer resistance to enfuvirtide also result in reduced replication capacity / 
replicative fitness of the virus [96]. This is presumably due to adaptations in the gp41 domain that 
reduce enfuvirtide binding, but consequently reduce the efficiency of six-helix bundle formation and 
overall fusion rates [97]. These mutations did not confer cross resistance to other types of entry 
inhibitors (attachment inhibitors or coreceptor inhibitors) [98] but did sensitize viruses to 
neutralization by monoclonal antibodies that target the gp41 domain, presumably by prolonging the 
exposure of fusion intermediates that are specifically sensitive to these antibodies [97]. Adaptation to 
enfuvirtide has even resulted in viruses that require enfuvirtide for fusion [99].  
Though it is clear that gp41 resistance mutations, taken out of the context of the envelope under 
selection, result in decreased fusion efficiency and reduced viral fitness, the function of envelope 
context seems to modulate the overall effect of these mutations in vivo [100]. Studies of baseline 
susceptibility to enfuvirtide suggested that large variations in intrinsic susceptibility existed in diverse 
HIV-1 isolates, and that these variations mapped to regions outside the enfuvirtide binding site [101]. 
Sequences associated with the V3 loop were correlated with intrinsic enfuvirtide susceptibility, 
suggesting that interactions with the coreceptor were important determinants of susceptibility of a drug 
that inhibits virus fusion. A seminal observation in the understanding of entry inhibitor susceptibility 
was made in 2002 by the discovery that the efficiency of the fusion process was the principal 
modulator of intrinsic enfuvirtide susceptibility [102]. Mutations in the coreceptor binding site that 
reduced gp120 affinity for CCR5 resulted in viruses with reduced fusion kinetics [103,104]. 
Engagement of CD4 by gp120 initiates a process of structural rearrangement in the envelope 
glycoprotein resulting in fusion. Completion of this process requires engagement of the coreceptor 
molecule, but enfuvirtide susceptibility is limited to the time between CD4 engagement and six-helix 
bundle formation. Thus efficiency of this process affects the amount of time that enfuvirtide has to 
bind gp41 and prevent fusion. Any change in the system that decreases rate of fusion (e.g., reducing 
the levels of coreceptor expression) also increases susceptibility of virus to inhibition by enfuvirtide. 
Consistent with this, ENF is synergistic with compounds that inhibit CD4 or coreceptor engagement 
[105-107]. 
5.3. Chemokine Analogs  
Discovery of the chemokine coreceptors was facilitated by the observation that native chemokines 
can inhibit HIV-1 replication [44]. Thus the first attempt to generate a coreceptor based entry inhibitor 
was modulation of the endogenous chemokine RANTES (CCL5) to produce a more potent version. 
Modulation of the N-terminus by deletion of the N-terminal methionine residue resulted in increased 
potency of the chemokine RANTES [108]. Addition of an aminooxypentane moiety to the N-terminus 
of either RANTES or MIP-1αP resulted in further increases in potency and increases in affinity for 
CCR5 [108,109]. Modulation of the N-terminus of the chemokine was specifically chosen because it 
appears that chemokines interact selectively with specific receptors by a “message” and “address” Viruses 2010, 2                                       
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system. The core domain of the chemokine is specifically responsible for determining receptor 
specificity (the address), while the N-terminus of the chemokine is involved in elicitation of 
downstream signal transduction cascades (the message) [110]. An HIV-1 inhibitory molecule should 
ideally not induce signal transduction cascades or the ensuing lymphocyte activation or chemotaxis. 
Modifications made to generate met-RANTES and AOP-RANTES resulted in abrogation of 
chemotaxis signals but not calcium flux [108,111]. This signaling cascade induced by RANTES 
derivatives can lead to an activation of HIV-1 replication, which can counter the effects of this analog 
on entry inhibition [108].  
One major principal for the development of chemokine-like inhibitors is the ability of chemokines 
to induce ligand-mediated internalization of their receptor through a clathrin-dependant mechanism. 
Chemokine receptors, when bound by ligand and in their signaling-active state, activate G protein-
coupled receptor kinases (GRKs). GRKs phosphorylate the C-terminal cytoplasmic domain of the 
chemokine receptor. The phosphorylated form of the receptor is recognized by β-arrestin, which 
recruits scaffolding proteins and clathrin precursor proteins to the receptor. Clathrin-coated pits form 
invaginations and the receptor is internalized. CCR5 is specifically endocytosed and moved to a 
recycling endosomal compartment [112]. Contribution of receptor downregulation in inhibition of 
HIV-1 entry by chemokines was first observed for inhibition of X4-tropic HIV-1 isolates by SDF-1 
[113]. Analysis of a series of RANTES analogs revealed that their potency in blocking HIV-1 entry 
correlated not with their binding affinity, but with their ability to induce ligand-mediated 
internalization of CCR5 [114]. Consistent with this, mutagenesis of the CCR5 C-terminus, abrogating 
its recognition and phosphorylation by GRKs, resulted in a mutant that is not internalized when bound 
by ligand. Use of this mutant significantly reduced the potency of AOP-MIP-1αP during the course of 
short term virus exposure (<12hrs) [115]. Beyond simple receptor internalization, it has been found 
that chemokine analogs result in prolonged sequestration of cell surface receptor [116]. The 
mechanisms behind prolonged sequestration of CCR5 have been explored but have not been fully 
elucidated. Further iterative design of the RANTES N-terminus resulted in a third generation 
compound, PSC-RANTES, with even higher potency than AOP-RANTES [117]. PSC-RANTES has 
been shown to block vaginal transmission in the SHIV-Macaque model system [118] and is currently 
in development as a microbicide to prevent sexual transmission of HIV-1.  
In some of these macaques treated with high PSC-RANTES concentrations (100μM), a selection of 
PSC-RANTES resistance variants was confirmed and as described below, resistance was likely 
conferred by increased coreceptor affinity. In relation to the mechanism of PSC-RANTES inhibition, 
altered PSC-RANTES or AOP-RANTES sensitivity in primary HIV-1 isolates that remain CCR5-
using is likely in the context of either differential binding of virus versus drug on the CCR5 receptor, 
increased affinity of the virus for the receptor, or more rapid entry kinetics. However, CCR5-
dependent resistance as opposed to coreceptor switching indicates that the mechanism of PSC-
RANTES derivative inhibition cannot be solely due to receptor-ligand internalization or sequestration 
from the cell surface. Studies suggest that competitive inhibition may even be a dominant mechanism 
by which PSC-RANTES or other RANTES derivatives block HIV-1 entry [119]. 
A major problem associated with chemokine analogs is their residual capacity to signal through 
CCR5 and through cell surface proteoglycans [111,120]. This residual activity has been associated 
with stimulation of viral replication by enhancement of viral integration [121] and through Viruses 2010, 2                                       
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enhancement of virus entry [122]. AOP-RANTES, like RANTES, has been shown to activate mitogen-
activated protein kinases and pertussis-toxin sensitive signals [121,123]. High concentrations of 
chemokine analogs clearly have a stimulatory effect on T cells, and are formally considered partial 
agonists of CCR5. This residual signaling activity may limit the effectiveness and potential use of 
chemokine analogs in vivo.  
5.4. Small Molecule CCR5 Antagonists 
Small molecule CCR5 antagonists bind to hydrophobic pockets within the transmembrane helices 
of CCR5 [124,125]. This site does not overlap the binding sites of either CCR5 agonists or HIV-1 
envelope, but instead induces and stabilizes a receptor conformation that is not recognized by either. 
Thus, these molecules are considered allosteric inhibitors. Ideally, a small molecule inhibitor of CCR5 
would block binding by HIV-1 envelope but continue to bind native chemokines and facilitate signal 
transduction. Most small molecule inhibitors, however, are pure antagonists of the receptor. Oral 
administration of small molecule antagonists has been demonstrated to inhibit viral replication in 
macaque models [126] and to prevent vaginal transmission [127]. Thus far, three antagonists (VCV, 
MVC, and Aplaviroc) have been shown to inhibit virus replication in humans [128]. The compound 
maraviroc (MVC) has been tested in phase III efficacy trials and was approved for therapeutic use by 
the FDA in 2007.  
Maraviroc is a selective small molecule CCR5 antagonist currently being used to treat patients with 
resistance to multiple HIV drugs but has been recently approved for first-line treatment regimens. 
Identified in a chemokine binding assay screen of a Pfizer compound library, maraviroc is an 
imidazopyridine that binds a hydrophobic transmembrane cavity of CCR5. Alanine scanning 
mutagenesis of the transmembrane domains of CCR5 revealed key residues in domains 1, 2, 3 and 7 
for small molecule binding [124]. Binding alters the conformation of the second extracellular loop of 
the receptor, preventing its interaction with the V3 stem loop of HIV’s gp120 envelope glycoprotein 
[124,129]. Ligand binding competition assays indicated maraviroc prevented C-C chemokine ligand 
binding to CCR5 with IC50 values (concentration of drug required to inhibit viral replication by 50% in 
culture) in the nanomolar range. Additionally, it inhibited chemokine-induced signaling of intracellular 
calcium redistribution, however it did not trigger calcium signaling upon binding up to 10μM [128]. In 
the same study, maraviroc was shown to have potent antiviral activity against a panel of primary 
CCR5-tropic HIV-1 isolates with a mean IC90 of 2 nM. 
The MOTIVATE 1 (conducted in North America) and MOTIVATE 2 (conducted in Europe, 
Australia, and the US) phase III clinical trials sought to study the safety and efficacy of maraviroc in 
multi-drug resistant patients harboring R5 tropic viruses. (MOTIVATE stands for Maraviroc versus 
Optimized Therapy In Viremic Antiretroviral Treatment Experienced patients) Results from these 
trials published in 2008 indicated patients receiving maraviroc (either once or twice daily) plus an 
optimized background therapy (OBT) showed significant reductions in HIV-1 RNA levels and 
increases in CD4 cell counts versus patients receiving OBT alone [130,131]. Preliminary results from 
these trials resulted in FDA approval of maraviroc for clinical use in 2007. It is currently marketed as 
SELZENTRY by Pfizer, Inc. Since its approval, maraviroc has been utilized as a salvage therapy for 
multi-drug resistant patients with R5 tropic virus. Viruses 2010, 2                                       
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Vicriviroc is another CCR5 inhibitor by Schering Plough currently in phase III clinical trials that 
binds a similar transmembrane pocket as maraviroc. Preliminary results from the vicriviroc clinical 
trials indicate a reduction in viral load in patients taking vicriviroc in combination therapy [132]. In 
addition to maraviroc and vicriviroc, several other small molecule inhibitors are in various stages of 
development (Table 2). Aplaviroc was developed as a small molecule CCR5 antagonist to block HIV-1 
entry but GlaxoSmithKline halted development in a phase II trial due to strong evidence of hepatic 
toxicity [133]. 
6. Resistance to Coreceptor Inhibitors 
As with any antiretroviral, resistance to entry inhibitors will inevitably arise. However, their 
resistance profile will be unlike any other class of antiretroviral since they bind to a host cell protein, 
not a viral protein. Potential mechanisms of resistance could include 1) tropism switching (utilization 
of CXCR4 instead of CCR5 for entry), 2) increased affinity for the coreceptor, 3) utilization of 
inhibitor-bound receptor for entry, and 4) faster rate of the entry step. A general schematic of HIV-1 
inhibition by and resistance to a CCR5 or CXCR4 agonist/antagonist is provided in Figure 3. 
6.1. Tropism Switching  
The major concern in the therapeutic administration of coreceptor inhibitors is the possibility that 
resistance will manifest by a change in coreceptor tropism from CCR5 to CXCR4, or that an outgrowth 
of an X4-tropic virus subset will come to dominate the intrapatient virus population. The mechanisms 
and consequences of coreceptor switching are poorly understood at this time. It is unclear what factors 
drive this switch, or why switching is generally limited to late phases of disease progression. Indeed, it 
is not clear at this time whether a switch from R5 to X4 tropism is a cause or consequence of disease 
progression.  
On the other hand, resistance to a variety of small molecule CCR5 inhibitors has been generated by 
passage of inhibitor-susceptible virus isolates in sequential dose escalations of drug. These 
propagations have been performed in PBMC cultures, which express CCR5 and CXCR4, as well as a 
variety of other chemokine receptors that have been previously implicated as potential HIV-1 
coreceptors. In these experiments, inhibitor-resistant viruses continue to require CCR5 for entry and 
cannot utilize either CXCR4 or any alternative coreceptors [134,134-137] (Figure 3). Furthermore, 
evaluation of coreceptor tropism of viruses derived from patients who failed maraviroc therapy during 
the MOTIVATE trials indicate that tropism changes occurred only when X4 tropic viruses were pre-
existing in the patient quasispecies [138]. Of 1042 patients with R5 tropic virus at the time of 
enrollment, 228 patients reportedly failed treatment. Of these failures, 133 were receiving maraviroc 
and of these 76 patients were found to harbor dual or mixed tropic virus at the time of failure [131]. 
Tropism testing revealed that these patients had pre-existing populations of X4-tropic virus prior to the 
start of the trial, which was below the level of detection of the tropism assay used at the time of 
enrollment. Another trial specifically studying effects of maraviroc on patients with non-R5 tropic 
virus found no benefit in maraviroc treatment versus placebo [139]. Thus it appears that, though 
outgrowth of pre-existing X4-tropic viruses in the quasispecies remains a problem for the therapeutic Viruses 2010, 2                                       
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administration of CCR5 antagonists, de novo mutations conferring altered coreceptor usage may not be 
the favored pathway for resistance in vitro or in vivo.  
Figure 3. Schematic of HIV-1 resistance to co-receptor inhibitors based on putative co-
receptor switch or binding of the drug bound inhibitor. Resistance to CCR5 inhibitors (top) 
or CXCR4 inhibitors (bottom) can manifest as a change in co-receptor tropism (center) or 
the virus acquiring the ability to utilize inhibitor-bound forms of the co-receptors (right top 
and bottom). 
 Viruses 2010, 2                                       
 
 
1083
It is important to note that a coreceptor switch or evidence of pre-existing CXCR4 tropic virus only 
provide a reason for 76 of 133 MVC failures. As described below, four of the MVC treatment failures 
may relate to use of CCR5 even in the presence of MVC. However, 55 MVC treatment failures remain 
unexplained at the time of this publication. Recent studies suggest a possible discrepancy between 
differential sensitivity to CCR5 antagonists in various phenotypic assays. For example, susceptibility 
to entry inhibitors, specifically CCR5 antagonists, can be modulated dependent on cell type, state of 
cellular activation, and number of virus replication cycles [119,134,136,140]. Also, different primary 
HIV-1 isolates can vary in sensitivity to entry inhibitors as much as 100-fold in IC50 values [119,128]. 
This difference is much more demonstrable with infection assays using replication competent primary 
HIV-1 isolates as compared with defective viruses limited to single cycle replication. In 2005, Dorr et  
al. reported less than a 10-fold variation in MVC sensitivity with envelope pseudotyped viruses. In 
contrast, primary isolates in multiple cycle assays displayed a 100-fold variation in MVC sensitivity 
but only a 10-fold inhibition difference in single cycle assays [128]. Thus, it is quite possible that the 
remaining 55 failures in the MOTIVATE trials might relate to sensitivity of the infecting virus to 
MVC prior to treatment or simply, the inability to detect MVC resistance at the time of treatment 
failure with existing assays. 
6.2. Competitive Resistance Model: Increased Coreceptor Affinity 
If coreceptor switching is not the main mechanism of resistance to small molecule coreceptor 
inhibitors, then it is important to understand by what mechanism resistance does arise. Two models of 
resistance have been proposed: competitive and noncompetitive resistance (Figure 4). In the 
competitive resistance model, gp120 interacts with CCR5 with a given affinity. In the presence of an 
inhibitor (green), the high affinity interaction between receptor and inhibitor blocks the lower affinity 
interaction between the receptor and gp120 (Figure 4c). Adaptations in gp120 increase the affinity 
relationship between envelope and coreceptor, and this change in receptor affinity is sufficient for 
gp120 to compete inhibitor off of the receptor (Figure 4f). Experimental evaluation of this resistance 
mechanism would appear as a shift in IC50 value and complete inhibition of virus entry can be 
achieved by increasing the concentration of inhibitor (Figure 4g). Many questions about this potential 
form of resistance can be raised: 1) what are the baseline affinities of each contact point between 
gp120 and coreceptor? 2) How great are the variations among HIV-1 isolated in these baseline 
affinities? 3) What types of change in the gp160 sequence would result in greater coreceptor affinity? 
4) How great a change in affinity is required to result in differential inhibition by a given drug? 5) Will 
gp120 adapt to different CCR5 inhibitors by a similar pathway, or by alternative mutations for each 
drug (i.e., will cross resistance be a problem)? 6) What are the consequences of affinity changes on 
overall viral replication? 7) What are the consequences of affinity changes on viral dynamics in vivo 
and disease progression? Much work is still required to substantially address these issues.  
6.3. Non-competitive Resistance Model: Utilization of Inhibitor-bound Coreceptor 
The second model of resistance to coreceptor inhibitors is noncompetitive resistance (Figure 4). In 
this scenario, a small molecule inhibitor binds CCR5 in an allosteric site, which induces and/or 
stabilizes a receptor configuration that is not recognized by HIV-1 envelope (or native chemokines). Viruses 2010, 2                                       
 
 
1084
Due to the lack of recognition, receptor docking is blocked and the HIV-1 entry process cannot 
proceed (Figure 4b). Adaptation to this type of inhibition is mediated by changes in gp120 that allow 
for recognition of the CCR5 configuration induced by inhibitor binding in the allosteric site. The 
overall affinity for the inhibitor-free receptor may not be relevant in this circumstance, and the 
envelope can complex with the inhibitor-bound configuration of CCR5 (Figure 4e). Experimental 
evaluation of noncompetitive resistance is manifested by a plateau effect on HIV-1 entry as inhibitor 
concentration increases (Figure 4g). In this case, the overall extent of inhibition never reaches 100% 
independent of the concentration of inhibitor. Evaluation of inhibition curves would reveal that the 
EC50 for an inhibitor resistant virus (defined as the half-plateau height, or the concentration at which 
the inhibitor achieves 50% of its maximal effect) is equal to the IC50 of the inhibitor against the 
inhibitor-sensitive variant of the virus. The plateau effect is caused by differences in the efficiency of 
usage of the inhibitor-free and inhibitor-bound form of the receptor. Thus a completely sensitive virus 
uses the inhibitor-bound form of CCR5 with 0% efficiency. A virus that uses the inhibitor-bound form 
of CCR5 with equal efficiency as the inhibitor-free form of CCR5 would not indicate any level of 
inhibition. Consequently, any virus adaptation that would cause an increase in the efficiency of use of 
the inhibitor-bound receptor over the efficiency of use of the inhibitor-free receptor would yield a 
negative inhibitory value, or an apparent enhancement of infection in the presence of saturating levels 
of inhibitor. This has led to redefining phenotypic resistance as a reduction in the maximal percent 
inhibition (MPI) <95% rather than a classical shift in IC50 values. The pattern of mutations in env 
conferring this drug resistant phenotype, i.e., entry through drug-bound receptor, is largely unknown 
but could be related to V3 loop mutations (Table 3). In vivo, this resistance mechanism has been 
observed in several studies. For example, an HIV-1 subtype C infected patient treated with vicriviroc 
failed treatment and was shown to harbor virus capable of replicating even at the highest drug 
concentration (1μM) [141]. With this patient’s HIV-1 envelope, there was no apparent shift in IC50 
values to VCV. Resistance to PSC-RANTES was observed in macaque microbicide studies and the 
SHIV env variant was capable of replicating even at 100 nM of drug, a concentration 100-fold above 
the IC50 for wild type SHIV env [142]. In contrast to the observation with VCV resistance, this PSC-
RANTES resistant virus displayed a shift in drug susceptibility curve suggesting that increased binding 
affinity for native CCR5 and displacement of PSC-RANTES versus PSC-RANTES bound CCR5 may 
be more dominant in the drug resistant phenotype. This combination in mechanisms has also been 
observed in resistant HIV-1 isolates selected under VCV selective pressure in vitro [134].  
During the MOTIVATE clinical trials, several patients failed treatment yet maintained CCR5 
tropism. While some of these patients experienced treatment failure as a result of opportunistic 
infections, a subset experienced failure as a result of apparent resistance to maraviroc. Clonal analyses 
of the env regions of viruses from these patients indicated changes had occurred in the V3 loop of 
gp120 as compared to viruses isolated at the time of enrollment. However, the pattern of mutations 
was different in each patient implying multiple pathways to resistance were possible [143].  
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Figure 4. Models of Resistance to HIV-1 Entry Inhibitors. Two models for resistance to HIV-1 
coreceptor inhibitors have been proposed. The noncompetitive model has been proposed for 
resistance to small molecule allosteric inhibitors of CCR5 (such as maraviroc, vicriviroc and 
TAK-779). In this model, (b)  envelopes that are sensitive to inhibition cannot recognize the 
configuration of the inhibitor bound receptor. (e) Inhibitor-resistant variants can recognize the 
inhibitor-bound receptor complex. (g) Entry inhibition assays result in a plateau effect, and the 
height of this plateau is indicative of the efficiency with which the HIV-1 envelope utilizes the 
inhibitor-bound form of CCR5 relative to the inhibitor-free receptor (a virus that cannot use the 
inhibitor-bound complex is indicated in blue diamonds, while a virus that uses the inhibitor-
bound form of CCR5 with 35% efficiency as compared to the inhibitor-free receptor is indicated 
in red squares). In this model the maximum rate of the reaction (1/V) reduces in the presence of 
inhibitor without changing the binding affinity (1/[S]) of the substrate for the receptor. The 
competitive model may be the most relevant for inhibitors that block HIV-1 envelope binding by 
steric hindrance (chemokines, antibodies to CCR5). In this model, (c) an inhibitor bound receptor 
is not accessible by HIV-1 envelope proteins with low overall affinities for receptor, (f) whereas 
envelope proteins with mutations that confer high affinity can compete off the inhibitor for 
interaction with the receptor. (g) This resistance mechanism is manifested in entry inhibition 
assays by a fold change in IC50 value (sensitive virus is depicted by blue diamonds, while a 
resistant variant is depicted by red squares). In this model, increasing inhibitor concentrations 
result in successful inhibition (100%) of entry. The affinity of the substrate to the binding site is 
decreased while the maximum velocity of the reaction remains unchanged. 
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Figure 4. Cont.  
 
 
Currently, there is limited data available from in vitro resistance studies. However, a few studies 
have described in vitro generated resistant variants of primary HIV-1 isolates. In 2006 maraviroc 
resistant variants were generated from two different primary HIV-1 isolates, RU570 (clade G) and 
CC1/85 (clade B), by sequential passage in the presence of maraviroc [136]. Both resistant viruses 
possessed distinct amino acid changes in the V3 loop of gp120 as compared to control virus passages 
(Table 3). For CC1/85res virus A316T and I323V mutations were observed in the V3 loop while the 
RU570res virus had a three amino acid (QAI) deletion from residues 315-317. Both resistant viruses 
had additional mutations in other regions of env outside of V3 but site-directed mutagenesis studies of 
molecular clones created from CC1/85res indicated that the V3 loop changes were responsible for 
conferring maraviroc resistance. The reduction in MPI observed for the resistant viruses indicated 
these viruses were able to utilize inhibitor-bound receptor for entry. To further support this hypothesis, 
maraviroc resistant viruses that were susceptible to aplaviroc (a CCR5 inhibitor that binds to a similar 
region as maraviroc) were unable to be inhibited by aplaviroc in the presence of high concentrations of 
maraviroc. 
Studies describing other resistant primary isolates vary widely in adaptive amino acid changes 
observed in the envelope proteins. Genotypic and phenotypic analysis of CC1/85 passage variants that 
ultimately gave rise to resistance to AD101 indicated that resistance arose via stepwise accumulation 
of mutations in the V3 region of gp120 [140]. A single mutation was selected for in V3 after four to six 
passages in the presence of AD101 that resulted in modest resistance (three-fold) through an apparent 
competitive mechanism. This variant had increased capacity to utilize low levels of CCR5 [135] and is 
hypothesized to have greater overall CCR5 affinity. Upon continued passage, three more mutations 
arose in the V3 which led to complete insensitivity to AD101. Inhibition studies of virus clones 
bearing these four mutations resulted in a plateau effect which indicated the virus was using the Viruses 2010, 2                                       
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inhibitor-bound CCR5 complex with approximately 90% efficiency of the inhibitor-free form of 
CCR5, though cell type differences in plateau height did exist [144]. However, adaptation to vicriviroc 
of this same primary isolate did not involve changes in the V3 region, suggesting that resistance can 
arise through alterations in envelope geometry that are not restricted to specific sites within the 
envelope glycoprotein [134,145]. These studies suggest that viruses from the same primary isolate can 
follow multiple genetic pathways to resistance.  
Table 3. V3 loop resistance mutations of CCR5 small molecule resistant viruses. 
Resistant virus  V3 Loop resistance mutations
(HXB2 numbering) 
Reference 
CC1/85 – Maraviroc   316T  
323V  
[136] 
RU570 – Maraviroc   QAI deletion 315-17   [136] 
RU570 - Vicriviroc   305R  
315Q  
319T  
[146] 
D101.12-Vicriviroc 
(CC1/85 derived)  
308P   [134] 
CC101.19 – AD101  
(CC1/85 derived)  
305R  
308P  
316V  
321E  
[140] 
Week 28 in vivo patient 
isolate- Vicriviroc  
305R  
306P  
307I  
316I  
318R  
319E  
[141] 
 
Additional reports of chemokine receptor directed small molecule resistant viruses have largely 
implicated mutations in the V3 region as necessary and sufficient for resistance. Mutations in the V3 
loop sequence of virus from the subtype C infected individual harboring VCV resistant virus were 
found sufficient to confer vicriviroc resistance [141]. More specifically the emergence of the S306P 
mutation was associated with complete resistance to vicriviroc in chimeric clones. Utilizing the clade 
G primary isolate RU570, a vicriviroc resistant variant was isolated and mutations in the V3 loop and 
C4 region were identified as responsible for conferring resistance [146]. Resistance to TAK-652 
manifested as changes in the V3 loop as well as other regions of gp160 [137]. A single K315R 
mutation in the V3 loop of SHIVSF162-p3 conferred at least 10-fold resistance to PSC-RANTES, which 
was selected under a single dose of drug applied as a microbicide [142]. More importantly, virus 
harboring the K315R mutation was still capable of replicating in the presence of 100 nM PSC-
RANTES or a concentration at least 100-fold above the IC50 value for the wild type virus. Ultimately, Viruses 2010, 2                                       
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the changes required in gp120 to allow for recognition of inhibitor-bound forms of CCR5 are unclear, 
and the alterations in the geometry of the envelope – receptor complex remain a mystery. 
Of note is that several of the studies describing generation of resistant viruses have utilized primary 
isolate CC1/85 or a derivative clone to generate resistance to maraviroc, vicriviroc, or AD101 
[134,140,147]. This parental virus was derived from a subtype B individual in 1985 that had viruses 
only able to use CCR5. Use of this single primary isolate has resulted in multiple sets of mutations 
conferring resistance to each of these drugs implying multiple pathways of resistance can be followed 
by the same virus. Only two studies have described resistance developed in a non-subtype B virus 
(clade G RU570) against maraviroc and vicriviroc [136,146]. There is a clear need for more studies 
characterizing small molecule resistance in non-subtype B isolates. 
Cross-resistance has been described for some but not all of the in vitro derived resistant variants. 
Two maraviroc resistant variants remained susceptible to other small molecule CCR5 antagonists and 
the fusion inhibitor enfurvitide [136]. In contrast, vicriviroc resistant variants acquired resistance to the 
modified chemokine derivatives PSC-RANTES and AOP-RANTES as well as other small molecule 
CCR5 inhibitors, namely AD101, SCH-C, and CMPD 167 [134]. An AD101 resistant variant acquired 
resistance to the small molecule SCH-C yet remained susceptible to inhibition with the chemokine 
ligand RANTES [140]. Therefore the implications of the development of resistance to one small 
molecule CCR5 inhibitor to cross-resistance to other members of this class are not yet clear. 
In summary, mutations associated with resistance to CCR5 antagonists in in vitro derived resistant 
isolates have largely mapped to the V3 region of gp120 with the exception of two viruses with resistant 
mutations in other regions of gp160. However, resistance in clinical trial patients failing treatment with 
R5 tropic viruses have all been attributed to mutations in the V3 loop arising during therapy [141,143]. 
While cross-resistance has been reported for some resistant variants, others have remained susceptible 
to small molecule inhibitors.  
7. Intrinsic Resistance to Entry Inhibitors 
Primary HIV-1 isolates display a wide range of susceptibilities to entry inhibitors, with 50% 
inhibitory concentrations (IC50) varying by as much as 1000-fold. This is in significant contrast to 
inhibitors of reverse transcription and protease cleavage, which exhibit modest differences in intrinsic 
sensitivity across diverse HIV-1 isolates. Large susceptibility variations in primary HIV-1 isolates 
have been documented for the chemokine derivative AOP-RANTES [148], the fusion inhibitor 
enfuvirtide (ENF, T-20) [102,103,149], and many small molecule coreceptor antagonists [TAK-779 
[102,150], maraviroc [128], SCH-C [150], vicriviroc [151], and AMD-3100 [149]. Due to the high 
degree of diversity among HIV-1 env genes of the same or different HIV-1 subtypes, it is difficult to 
identify specific sequence variations that may be associated with variable sensitivity to entry 
inhibitors. 
Evaluation of intrinsic sensitivity differences to T-20 and TAK-779 revealed that kinetic factors of 
fusion were largely responsible for variations in IC50 [102]. Sensitivity to T-20 mapped to the V3 loop 
of env [101], but mutations in the bridging sheet are also sufficient to modulate intrinsic susceptibility 
to these inhibitors [102,103]. Multiple factors are involved in the efficiency of host cell entry. Upon 
CD4 binding, structural rearrangements within the envelope occur which reveal the coreceptor binding Viruses 2010, 2                                       
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site. The current model of ternary complex formation favors multiple interaction sites between HIV-1 
envelope and CCR5. The bridging sheet and V3 stem interact with the CCR5 N-terminus, while the V3 
crown interacts with the second extracellular loop of CCR5. The hypervariable V3 loop must evolve 
by balancing attempts to escape host humoral response with the need to engage the CCR5 coreceptor 
for host cell entry. The affinity relationship between CCR5 and envelope, which can be modulated by 
the density of CCR5 on the cell surface, may be important in influencing the efficiency of entry. Some 
views hold that the major rate-limiting process in host cell entry is the formation of six-helix bundles 
[152], but other data suggests that ternary complex formation is the major rate-limiting step of the 
entry process [153]. The affinity relationship between CCR5 and V3 may be important in influencing 
the efficiency of entry through either of these pathways.  
Mechanisms involved in variable susceptibility to chemokines such as RANTES or their derivatives 
have not been evaluated. These inhibitors differ from small molecule CCR5 antagonists in their ability 
to occupy surface receptor as well as trigger internalization of CCR5 [114]. A >30-fold difference in 
intrinsic susceptibility to the CCL5 analog AOP-RANTES was observed with a panel of primary  
HIV-1 isolates from all subtypes [148]. This variability in AOP-RANTES sensitivity may be related to 
sequence differences in the V3 crown, specifically at positions 318 and 319 (HXB2 numbering). 
Similar variations at position 319 were observed when comparing intrinsic sensitivities of a different 
panel of primary isolate viruses to inhibition by TAK-779 and SCH-C [150]. Further underscoring the 
potential relevance of these sites in intrinsic entry inhibitor sensitivity, treatment of HIV-infected   
hu-PBL-SCID mice with the CCL5 analog NNY-RANTES selected for mutation at position 318 in the 
challenge virus, suggesting a potential role of this polymorphism in escape [154].  
Subsequent studies revealed that the most common polymorphisms at positions 318 and 319   
(e.g., 318Y and 319A) in the V3 loop showed the greatest intrinsic resistance to not only RANTES 
derivatives but also inhibition by enfuvirtide and TAK-779 [155]. In contrast, the more rare 
polymorphisms (but still found as wild type sequence) such as 318R and 319T were hypersusceptible 
to these entry inhibitors. These findings also revealed that the more common polymorphisms in HIV-1 
env may have evolved to increase replicative fitness, escape neutralizing antibodies, and avoid the 
inhibitory effects of CC-chemokines such as CCL3 (or RANTES). As a consequence of selected 
evolution, many primary HIV-1 isolates may be intrinsically resistant. However, this intrinsic 
resistance is highly context dependent. For example, substituting just the V3 loop coding region of a 
more sensitive primary HIV-1 isolate into a laboratory strain (more resistant) backbone resulted in 
demonstrable decrease in susceptibility to all entry inhibitors. Sensitivity to entry inhibitors increased 
when large segments of the env gene of primary HIV-1 isolates were substituted into the laboratory 
strain or when the primary isolates themselves were employed for drug susceptibility assays.  
Variations in the efficiency of the entry process may have an important role in the context of 
inhibiting HIV-1 entry in vivo. Many studies have looked at the baseline susceptibility of primary 
isolate HIV-1 viruses to inhibition by a broad range of entry inhibitors. As was seen with enfuvirtide, a 
wide range of susceptibility (>1000-fold) exists among primary HIV-1 isolates to molecules that 
inhibit at the level of the coreceptor [101,148-151,156]. The clinical relevance of such variations is 
unclear at this time. Furthermore, the mechanisms involved in these variations are not clear. The 
intrapatient population of viruses must infect cells in the presence of chemokine inhibitors, and some 
studies have suggested that viruses grow resistant to inhibition by chemokines over the course of  Viruses 2010, 2                                       
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HIV-1 infection in a single patient [157]. One possible consequence of this hypothesis is that virus 
variants found at acute infection may be more susceptible to entry inhibitors than variants found late in 
infection. Variations in coreceptor affinity may be involved in determining sensitivity to coreceptor 
inhibitors. 
8. Implications of HIV-1 Entry Efficiency 
HIV-1 envelope-mediated entry is a highly cooperative process. The efficiency of this process can 
be modulated by factors specific to the host cell, including receptor density on the surface, as well as 
expression of receptors in antigenically permissive conformations. Entry efficiencies are further 
modulated by the HIV-1 envelope both through quantitative factors such as receptor affinity as well as 
through qualitative factors of receptor interaction (e.g., envelope geometry and receptor-envelope 
stoichiometry). 
Several approaches have been taken to assess cooperativity in HIV-1 envelope mediated membrane 
fusion. The earliest study evaluated the effect of varying CCR5 expression levels on virus infection, 
and estimated that six CCR5 molecules were involved in a stable entry complex [158]. By titrating out 
functional envelope trimers using a dominant negative gp160 variant, it has been suggested that HIV-1 
entry can be achieved by a single trimer [159], and further that two subunits of the trimer are sufficient 
for entry [160]. This suggests that two CD4 molecules and two CCR5 molecules would be involved in 
this process. However, previous studies have implicated a role for at least four CD4 interactions in 
entry [161], and similar dominant negative gp160 approaches have suggested the involvement of 
between four and five trimers [162].  
There are several implications to the multiple receptor stoichiometry of HIV-1 entry. One 
assumption is that receptor density will play a significant role in entry efficiency, and furthermore, 
affinity relationships between envelope and CD4 as well as envelope and coreceptor will have 
implications on the rate and efficiency of entry. A stoichiometry requiring the aggregation of multiple 
CCR5 molecules to form a stable entry complex will be significantly inhibited in environments with 
limiting amounts of CCR5, such as in the presence of inhibitor. This prolongation of the entry step 
may allow for greater efficacy of various virus deactivation processes, such as endocytosis or 
complement mediated lysis.  
The efficiency of the HIV-1 entry process is thought to have implications for overall viral 
replicative fitness [163,164]. HIV-1 exists as a genetically variable population, or quasispecies 
[165,166] as a consequence of a high mutation rate (3.4 x 10
-5 per base pair) [1] and rapid turnover. 
Fitness is a complex factor within an infected host. In a simple model, intrinsic rates of viral 
replication determine the relative proportion of an HIV-1 clone in the overall population. Although low 
fitness variants can contribute to the genetic pool in the quasispecies theory, the most fit variants will 
dominate the population due to their competitive replicative advantage. Host selection is a major 
determinant of fitness in vivo. However, replicative fitness, also termed replication capacity (a measure 
of the growth kinetics of a virus) has important implications on viral fitness and pathogenesis. For 
example, viruses derived from long term nonprogressor cohorts have been shown to have lower 
replicative fitness than viruses from individuals with normal disease progression [167]. Viruses lacking 
the nef gene also have a replication defect in vitro, and these viruses are frequently associated with less Viruses 2010, 2                                       
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severe disease symptoms. Efficiency of virus entry may be an important determinant of viral 
replicative fitness, and consequently of viral pathogenesis.  
In the case of primary HIV-1 isolates, there is a direct relationship between replicative fitness and 
sensitivity to many entry inhibitors. As described earlier, primary HIV-1 isolates can evolve to higher 
replicative fitness in possible relation to avoidance of host immune response, higher cell tropism/entry 
efficiency, and possible avoidance of  chemokine inhibition [148,155,164]. These same selective 
pressures could result in viruses with increased binding affinity to co-receptor and higher rate of entry 
kinetics and as a consequence outcompete inhibitor or simply utilize inhibitor-bound CCR5 receptor. 
To support this hypothesis, HIV-1 envelopes derived from patients with elite suppression displayed 
reduced entry efficiencies, slow entry kinetics, and poor CCR5 utilization [168]. There was also a 
trend for these “elite” envelopes to be more sensitive to entry inhibitors. Lobritz et al. (2007) described 
a strong correlation between the replicative fitness and entry inhibitor sensitivity of HIV-1 harboring 
natural V3 polymorphisms [155]. This correlation was observed with PSC-RANTES, ENF, and the 
2D7 neutralizing antibody but not with TAK-779. The latter three drugs likely inhibit through a 
competitive mechanism whereas TAK-779 may be more of an allosteric, noncompetitive inhibitor. As 
a consequence, primary HIV-1 isolates are unlikely to evolve to utilize a coreceptor bound to a 
synthetic drug without a natural analog. Thus, resistance to drugs such as VCV or MCV might follow 
more classical selection of drug resistance and result in a fitness decrease.  
Very few studies have explored the fitness impact of HIV-1 with acquired resistance to CCR5 
agonist or antagonist and none have explored the HIV-1 fitness effects with actual MVC or VCV 
treatment of patients and emergence of resistance. However, two in vitro studies suggest that a 
decrease in fitness resulting from CCR5 inhibitor resistance may not be as common as with the fitness 
loss observed with resistance to almost all other antiretroviral drugs. Anastassopoulou et al. (2007) 
indicated that VCV-resistant variants selected in vitro were actually more fit or of similar fitness than 
the parental HIV-1 isolate [147]. In vaginal microbicide trials in macaques, PSC-RANTES selected for 
SHIVenv viruses with a single V3 and gp41 mutation that conferred resistance but actually increased 
replicative fitness over the infecting virus by at least 100-fold [142]. This increase in fitness was even 
greater when utilizing rhesus macaque CCR5 than human CCR5. Together these findings suggest that 
a major mechanism for resistance to CCR5 antagonists/agonists may relate to increased affinity for 
CCR5 and increased entry efficiency in the presence or absence of the drug.  
9. Conclusions  
Clearly many questions remain in our understanding of HIV-1 entry. It has become essential to 
answer many of these questions as inhibitors of the HIV-1 entry process begin widespread use in the 
treatment of HIV infection. The discovery and successful development of CCR5 entry inhibitors 
proves viral entry is a viable target for therapeutic intervention in HIV-1 patients. The only FDA 
approved CCR5 antagonist, maraviroc, has been utilized as salvage therapy for HIV patients harboring 
multi-drug resistant viruses and has recently been approved as therapy in treatment naïve patients. The 
propensity of HIV to develop drug resistance however, will ultimately result in treatment failures to 
this new class of inhibitors. Therefore it is of upmost importance to understand how resistance 
develops and by what mechanism(s) the virus is able to subvert inhibition. The research highlighted Viruses 2010, 2                                       
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here provides a starting point towards understanding the complex mechanisms of resistance to HIV-1 
entry inhibitors. 
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